University of Virginia Health System

EDUCATION:

University of Connecticut School of Medicine, MD, 1978
University of Connecticut , Resident, 1978 - 1980
University of California  , San Diego , Fellow Blood Banking, 1980 - 1982
Sloan-Kettering, Fellow Immunobiology, 1982 - 1983
Washington University  , Research Associate and Fellow, Laboratory Medicine, 1983 - 1985

CLINICAL:

Transfusion medicine with particular emphasis on cost containment and revenue enhancement strategies.

RESEARCH:

Calcium influx is a necessary component of the proliferative pathway in most types of cells. We are investigating this pathway with the intent of developing novel pharacological agents to inhibit cancer cell proliferation. A variety of techniques as used in this project including electrophysiological, pharmacological, and biochemical as well as rational drug design.

REFERENCES:

• Haverstick DM, Heady TN, Macdonald TL, and Gray LS . Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca²⁺ entry.  2000 Cancer Res. 60:1002.
• Gray MC, Lee S-J, Gray LS , Zaretzky FR, Otero AS , Szabo G, and Hewlett EL.  Translocation-specific conformation of adenylate cyclase toxin from Bordetella pertusis inhibits toxin-mediated hemolysis.  2001. J Bacteriol 183:5904.
• Gray LS, Perez-ReyesP, EP, GamorraP JC, Haverstick DMP, ShattockP M, McLatchieP L, HarperP JP, BrooksP G, HeadyP T, and Macdonald TL.  The role of voltage gated T type Ca²⁺ channel isoforms in mediating "capacitative" Ca²⁺ entry in cancer cells.  2004.Cell Calcium 36:489.
• McCalmont WF, Heady TN, Patterson JR, Lindenmuth MA, Haverstick DM, Gray LS, and Macdonald TL.  Design, synthesis, and biological evaluation of novel T-type calcium channel agonists.  2004. Bioorganic Med Chem, Lett. 14:3691.